Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Retained Earnings (2020 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed Retained Earnings for 6 consecutive years, with -$460.8 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 475151.55% to -$460.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$460.8 million through Dec 2025, down 475151.55% year-over-year, with the annual reading at -$460.8 million for FY2025, 475151.55% down from the prior year.
  • Retained Earnings hit -$460.8 million in Q4 2025 for Bolt Biotherapeutics, down from -$454.1 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $97000.0 in Q4 2024 to a low of -$460.8 million in Q4 2025.
  • Historically, Retained Earnings has averaged -$232.3 million across 5 years, with a median of -$264.2 million in 2022.
  • Biggest five-year swings in Retained Earnings: skyrocketed 100.03% in 2024 and later tumbled 1217797.22% in 2025.
  • Year by year, Retained Earnings stood at -$207.0 million in 2021, then tumbled by 42.56% to -$295.1 million in 2022, then decreased by 23.45% to -$364.3 million in 2023, then surged by 100.03% to $97000.0 in 2024, then crashed by 475151.55% to -$460.8 million in 2025.
  • Business Quant data shows Retained Earnings for BOLT at -$460.8 million in Q4 2025, -$454.1 million in Q3 2025, and -$447.0 million in Q2 2025.